Research - Affimed (AFMD) announced a licensing agreement with Roivant Sciences Monday after-market and Q3 business update this morning. Below we will outline the highlights from Q3 update and collaboration with Roivant. First, … Continue Reading
PremiumInsights - Pfizer (PFE) and BioNTech (BTNX) revealed that their COVID-19 vaccine was >90% effective in preventing the virus, compared to patients receiving placebo. This is a … Continue Reading
Read nowInsights - Tomorrow, Friday November 6, the FDA will hold an ADCOM for Biogen’s (BIIB) aducanumab. Aducanumab is a beta-amyloid drug for Alzheimer’s Disease that can receive … Continue Reading
PremiumInsights - Affimed’s (AFMD) ASH abstract for AFM13 was released today. The abstract (see here) covers AFM13 Phase 1 in relapsed/refractory CD30+ lymphoma patients. Affimed refers to this … Continue Reading
PremiumResearch - Iovance (IOVA) is up 35% since we opened a position on news that the company’s BLA was going to be delayed (read thesis here). This was … Continue Reading
PremiumInsights - Earlier this week, Affimed announced a collaboration with Korean company NKMax to investigate the combination of AFM24, an EGFR engager, with autologous NK cell product … Continue Reading
PremiumResearch - Concert Pharma (CNCE) is developing a deuterated d-serine as an add-on therapy to existing schizophrenia treatments. In historical academic papers, d-serine has shown to enhance the NMDA … Continue Reading
Premium
